A cikin Fabrairu 2023, Hukumar Abinci da Magunguna (FDA) ta haɓaka amincewar tucatinib (Tukisa, Seagen Inc.) da trastuzumab don kula da RAS daji mai nau'in HER2 mai cutar kansa wanda ya yaɗu ko kuma ba zai iya zama rem ba.
Nuwamba 2022: Haɗin doxorubicin, vincristine, etoposide, prednisone, da cyclophosphamide tare da brentuximab vedotin (Adcetris, Seagen, Inc.) Hukumar Abinci da Magunguna ta amince da ita don amfani a cikin yara.